Risk of Osteoporotic Fracture in Patients with Breast Cancer: Meta-Analysis

Overview

Journal J Bone Metab

Date 2020 Mar 20

PMID 32190606

Citations 5

Authors

Seeyoun Lee

Jun-Il Yoo

Young-Kyun Lee

Jung-Wee Park

Seokhyung Won

Jiung Yeom

Jin Woo Im

Seok Min Lim

Yong-Chan Ha

Kyung-Hoi Koo

Affiliations

Soon will be listed here.

Abstract

Background: The fracture risk induced by anti-estrogen therapy in patients with breast cancer remains controversial. The aim of this study was to perform a meta-analysis and systematic review to evaluate the risk of osteoporotic fracture in patients with breast cancer.

Methods: A systematic search was performed to identify studies that included any osteoporotic fracture (hip fracture and vertebral fracture) in patients breast cancer. Main outcome measures were occurrence and risk of osteoporotic fractures including hip and vertebral fractures in patients and controls.

Results: A systematic search yielded a total of 4 studies that included osteoporotic fracture outcomes in patients with breast cancer. Meta-analysis showed a higher risk of osteoporotic fracture in patients with breast cancer. Analysis of these 4 studies involving a total of 127,722 (23,821 cases and 103,901 controls) patients showed that the incidence of osteoporotic fractures was higher in the breast cancer group than in the control group. The pooled estimate of crude relative risk for osteoporotic fracture was 1.35 (95% confidence interval, 1.29-1.42; <0.001).

Conclusions: Although studies were limited by a small number, results suggested a possible association between anti-estrogen therapy and increased risk of osteoporotic fractures in patients with breast cancer.

Citing Articles

Efficacy of a single 5 mg zoledronic acid infusion in preventing bone loss and fracture in postmenopausal women with breast cancer.

Baek H, Shin K, Kim J, Jeong C, Lee J, Lim Y J Bone Miner Metab. 2024; 42(6):720-727.

PMID: 39349870 DOI: 10.1007/s00774-024-01552-0.

Is bone mineral density a prognostic factor in postmenopausal women with luminal A breast cancer?.

Lee S, Kim H, Jung Y, Kang S, Kim J, Yun M Korean J Clin Oncol. 2023; 19(1):27-31.

PMID: 37449396 PMC: 10352709. DOI: 10.14216/kjco.23005.

Fractures and long-term mortality in cancer patients: a population-based cohort study.

Ye C, Leslie W, Al-Azazi S, Yan L, Lix L, Czaykowski P Osteoporos Int. 2022; 33(12):2629-2635.

PMID: 36036268 DOI: 10.1007/s00198-022-06542-4.

Osteoporotic Fractures among Selective Estrogen Receptor Modulator Users in South Korea: Analysis Using National Claims Database.

Park J, Lee Y, Choi Y, Ha Y J Bone Metab. 2022; 29(2):75-82.

PMID: 35718924 PMC: 9208906. DOI: 10.11005/jbm.2022.29.2.75.

Bone health after RRBSO among mutation carriers: a population-based study.

do Valle H, Kaur P, Kwon J, Cheifetz R, Dawson L, Hanley G J Gynecol Oncol. 2022; 33(4):e51.

PMID: 35557034 PMC: 9250858. DOI: 10.3802/jgo.2022.33.e51.

References

Ueno T, Yamada M, Igarashi Y, Ogawa T . N-acetyl cysteine protects osteoblastic function from oxidative stress. J Biomed Mater Res A. 2011; 99(4):523-31. DOI: 10.1002/jbm.a.33211. View

Ettinger B, Pressman A, Sklarin P, Bauer D, Cauley J, Cummings S . Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab. 1998; 83(7):2239-43. DOI: 10.1210/jcem.83.7.4708. View

Tsai C, Tsa C, Muo C, Tzeng H, Tang C, Hsu H . Fracture in asian women with breast cancer occurs at younger age. PLoS One. 2013; 8(9):e75109. PMC: 3771894. DOI: 10.1371/journal.pone.0075109. View

Amir E, Seruga B, Niraula S, Carlsson L, Ocana A . Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011; 103(17):1299-309. DOI: 10.1093/jnci/djr242. View

Manolagas S . From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev. 2010; 31(3):266-300. PMC: 3365845. DOI: 10.1210/er.2009-0024. View

Boman A, Kokkonen H, Arlestig L, Berglin E, Rantapaa-Dahlqvist S . Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis. Clin Rheumatol. 2017; 36(5):1005-1012. PMC: 5400786. DOI: 10.1007/s10067-017-3570-4. View

Buzdar A, Robertson J, Eiermann W, Nabholtz J . An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002; 95(9):2006-16. DOI: 10.1002/cncr.10908. View

. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2016; 354:i4086. DOI: 10.1136/bmj.i4086. View

Hadji P . Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2008; 69(1):73-82. DOI: 10.1016/j.critrevonc.2008.07.013. View

10.

Fontani F, Marcucci G, Iantomasi T, Brandi M, Vincenzini M . Glutathione, N-acetylcysteine and lipoic acid down-regulate starvation-induced apoptosis, RANKL/OPG ratio and sclerostin in osteocytes: involvement of JNK and ERK1/2 signalling. Calcif Tissue Int. 2015; 96(4):335-46. DOI: 10.1007/s00223-015-9961-0. View

11.

Tremollieres F, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Perez-Lopez F . Osteoporosis management in patients with breast cancer: EMAS position statement. Maturitas. 2016; 95:65-71. DOI: 10.1016/j.maturitas.2016.10.007. View

12.

Rabaglio M, Sun Z, Price K, Castiglione-Gertsch M, Hawle H, Thurlimann B . Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol. 2009; 20(9):1489-1498. PMC: 2731016. DOI: 10.1093/annonc/mdp033. View

13.

Melton 3rd L, Hartmann L, Achenbach S, Atkinson E, Therneau T, Khosla S . Fracture risk in women with breast cancer: a population-based study. J Bone Miner Res. 2012; 27(5):1196-205. PMC: 3361522. DOI: 10.1002/jbmr.1556. View

14.

Hecht F, Pessoa C, Gentile L, Rosenthal D, Carvalho D, Fortunato R . The role of oxidative stress on breast cancer development and therapy. Tumour Biol. 2016; 37(4):4281-91. DOI: 10.1007/s13277-016-4873-9. View

15.

Nishimukai A, Higuchi T, Ozawa H, Yanai A, Miyagawa Y, Murase K . Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases. Breast Cancer. 2016; 24(2):245-253. DOI: 10.1007/s12282-016-0695-2. View

16.

Hsu L, Chu N, Kao S . Estrogen, Estrogen Receptor and Lung Cancer. Int J Mol Sci. 2017; 18(8). PMC: 5578103. DOI: 10.3390/ijms18081713. View

17.

Fata J, Kong Y, Li J, Sasaki T, Irie-Sasaki J, Moorehead R . The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000; 103(1):41-50. DOI: 10.1016/s0092-8674(00)00103-3. View

18.

Kalder M, Hadji P . Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer. Breast Care (Basel). 2015; 9(5):312-7. PMC: 4322683. DOI: 10.1159/000368843. View

19.

Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J . Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2009; 28(3):509-18. DOI: 10.1200/JCO.2009.23.1274. View

20.

Hofbauer L, Rachner T, Hamann C . From bone to breast and back - the bone cytokine RANKL and breast cancer. Breast Cancer Res. 2011; 13(3):107. PMC: 3218926. DOI: 10.1186/bcr2842. View